ABBV — Q2 2026 Financial Report Analysis
Q2 · Fiscal year 2026 · Published by Pham Hop · AI-drafted from the SEC filing
Revenue grew 9.5% on constant currency as Skyrizi and Rinvoq (both +24%) continue to outrun Humira's decline (-36%); GAAP EPS growth of 290% is a base-effect artifact of intangible amortization and contingent-consideration accounting, not operating performance.
Overview
AbbVie's net revenues grew 10.2% reported (9.5% on a constant-currency/operational basis) to $16.990 billion. The headline GAAP diluted EPS figure — $2.03, up 290.4% year-over-year — is not a useful performance indicator on its own: the reconciliation to adjusted EPS shows $0.81 per share of intangible asset amortization and $0.83 per share from a change in the fair value of contingent consideration, both non-operating accounting items rather than results of the underlying pharmaceutical business. Adjusted diluted EPS of $3.65, up 22.9%, is the more representative figure, and even that includes a $0.17 per share drag from acquired IPR&D and milestone expense this quarter.
Key Financial Metrics
| Metric | Q2 2026 | YoY Change |
|---|---|---|
| Net revenues | $16,990M | +10.2% (+9.5% operational) |
| GAAP diluted EPS | $2.03 | +290.4% |
| Adjusted diluted EPS | $3.65 | +22.9% |
| Immunology portfolio revenue | $8,786M | +15.1% |
| Skyrizi revenue | $5,505M | +24.4% |
| Rinvoq revenue | $2,525M | +24.5% |
| Humira revenue | $756M | -35.9% |
Takeaway: Skyrizi plus Rinvoq combined ($8.03 billion) now generate more than ten times Humira's remaining revenue ($756 million) — the post-patent-cliff transition that AbbVie has been managing for several years is now essentially complete in scale terms, and immunology segment growth (+15.1%) confirms the replacement franchise is still expanding, not just replacing what was lost.
Segment Detail
Immunology (Skyrizi, Rinvoq, Humira) grew 15.1% to $8.786 billion, still the primary growth engine. Neuroscience grew 20.3% to $3.228 billion, led by Vraylar (+18.9%) and Botox Therapeutic (+12.2%). Oncology declined 1.5% (2.4% operational) to $1.650 billion, dragged down by Imbruvica (-29.4%), which the release does not attribute to a specific cause but which is consistent with continued competitive and generic pressure typical of an aging oncology asset; Venclexta (+11.6%) and the newer Elahere (+33.1%) partially offset it. Aesthetics was roughly flat, up 0.3% reported but down 0.9% operational, with Botox Cosmetic up 5.2% and Juvederm down 6.0%.
Corporate Development
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in total equity value, adding clinical-stage immunology/inflammatory pipeline assets (zumilokibart, an IL-13 antibody for atopic dermatitis, and APG273, an IL-13/TSLP combination for asthma), both still in development rather than commercialized. The deal is expected to close in Q3 2026 and is guided to be $0.14 per share dilutive to 2026 adjusted EPS.
Outlook
AbbVie updated full-year 2026 adjusted diluted EPS guidance to $13.87-$14.07, down from $13.91-$14.11 — a $0.04 reduction at the midpoint, composed of $0.14 of dilution from the pending Apogee acquisition partially offset by $0.10 of first-half overperformance. Guidance continues to exclude any acquired IPR&D and milestone expense beyond what has already been incurred through Q2, which the company states it cannot reliably forecast — meaning further such charges, which have already cost $0.58 per share year-to-date, are a real possibility not reflected in the guidance range.
More AbbVie reports
Recent in Health Care
- IQVIA (IQV) · Q2 2026Revenue $4.4B (+8.7%) · EPS $1.53 (-0.6%)
IQVIA revenue rose 8.7% to $4.37B with both segments widening margins and a record $3.15B of R&D bookings (1.22x book-to-bill), but higher restructuring, stock pay, interest and tax left GAAP EPS at $1.53 vs $1.54; full-year guidance raised.
- Insulet Corporation (PODD) · Q2 2026Revenue $802M (+23.5%) · EPS $1.37 (+328.1%)
Insulet grew Q2 revenue 23.5% to $801.7M and beat its guidance, but cut its full-year U.S. Omnipod growth outlook to 17%-19%, citing what it is learning in type 2 diabetes, while pod-correction costs weighed on GAAP margins.
- Incyte (INCY) · Q2 2026Revenue $1.7B (+37.7%) · EPS $2.81 (+37.7%)
Incyte's Q2 2026 revenue rose 37.7% to $1.67B, lifted by a $246M one-time Opzelura Medicaid-rebate reversal; excluding it, net sales grew 17% as Jakafi rose 7% and newer drugs jumped 69%, and full-year sales guidance was raised to $5.13–5.26B.